

Aura Smart Air Ltd.

(the "Company")

This is an English translation of a Hebrew report of the company, that was published on May 15, 2022 (reference No. 2022-01-047295) at the ISA reporting website (magna.isa.gov.il) (hereafter: "The Hebrew Version"). The English version is only for convenience purposes. This is not an official translation and has no binding force. The translation in any case cannot perfectly reflect the Hebrew Version. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.

Attn:
The Securities Authority
www.isa.gov.il

Attn:
The Tel Aviv Stock Exchange Ltd.
www.tase.co.il

May 15, 2022

Re: **Success in the experiment to destroy the INFLUENZA A virus in confined spaces in a protocol that simulates a real situation**

The Company is honored to update you on the results of an experiment to prevent the spread in enclosed spaces of the INFLUENZA A influenza virus (the "**Virus**") carried in the air, using the Company's unique air purification system, the Aura Air system (the "**System**").

The experiment was conducted at the facilities of the Innovative Bioanalysis, Inc. laboratory in California, USA (the "**Laboratory**").¹ The Laboratory is approved for BSL-3 safety experiments level and requires strict practices, special safety equipment, and spaces designed in accordance with the guidelines of the American CDC (Centers for Disease Control and Prevention). This is for allowing the Laboratory to perform experiments also on dangerous pathogens that can cause serious or fatal diseases to humans through the respiratory system. The aim of the experiment was to perform a simulation in which the virus spreads in an enclosed space in an aerosol form and to determine the efficiency of the system in purifying the virus in enclosed spaces, in a way that allows cutting the aerosol infection chain (the "**Experiment**"). The following is the experiment room layout and the various systems as shown in the final Laboratory report:




Figure 1. Room layout for control and experimental trial.

¹ For more details about the Laboratory, see - <https://www.innovativebioanalysis.com/>.

Below are the experiment results:


Testing time Efficacy of virus neutralization in the tested space

After 15 minutes 63.69%

After 30 minutes 79.04%

After 60 minutes 99.998%

The results of the Experiment validate the system's impressive capabilities in real life to reduce by 99.998% the Virus presence in the air in a closed space in the size of 2.5 x 2.5 x 3 meters, within 60 minutes (the Company recommends running the system continuously and thus even reducing Virus neutralization times) . It should also be noted that already 15 minutes after the start of the Experiment, the system was found to be effective in reducing 63.69% of the Virus in the air, and after 30 minutes in reducing it by 79.04%. The following graph shows the results of the Experiment with respect to the time periods and presence of the Virus in the experimental space:



The results of the Experiment constitute another significant step in validating the system's capabilities, joining previous experiments performed by Sheba Tel-Hashomer Hospital, the Spanish Ministry of Defense, the Biological Institute at Campinas University in Brazil (as specified in section 6.8.2 of Chapter 6 of the Company's prospectus) in proving the capabilities of the Company's system in effectively neutralizing 99.98% of Coronavirus and even more resistant viruses. The Company intends to submit the results of the Experiment for AMR (accessories and medical devices) licensing in the Ministry of Health in order to provide policymakers and decision-makers with additional proven tools for cutting Virus infection chains in schools, nursing homes, public transportation, and other enclosed spaces.

As part of its research and development activities, the Company continues making experiments in various laboratories around the world, including the laboratory of Sheba Tel Hashomer Hospital, ranked by the prestigious Newsweek rating magazine in the top ten hospitals in the world for three years in a row, with the

aim of developing end technologies in the field of air quality management, including air monitoring, filtration and purification.

About the INFLUENZA A virus:

According to the CDC,² FluView's latest report shows that the weekly rate of U.S. influenza hospitalization for the week ending on April 30, 2022, was the highest weekly rate observed during that week in April since the 2010-2011 season. The extent of hospitalizations in the United States alone as a result of the Influenza virus is ranging about 300-700 thousand patients per season. In a 2003³ research, the damages of the Influenza virus were estimated at about 10 Billion dollars a year in the US only, as a result of direct health costs and about additional 16 Billion dollars a year in the US as a result of loss of income due to illness and death.

Kind Regards,
Aura Smart Air Ltd.
By: Aviad Schneiderman, CEO

² <https://www.cdc.gov/flu/weekly/index.htm>

³ <https://www.sciencedirect.com/science/article/pii/S0264410X07003854?via%3Dihub>